Notable risk factors for developing hydralazine-induced ANCA-associated vasculitis include a cumulative dose exceeding 100 g, prolonged therapy duration, female sex, slow hepatic acetylation, the presence of the null C4 gene, and a history of thyroid disease [1,3]. This evidence concerns the gene C4A and anti-neutrophil cytoplasmic antibody-associated vasculitis.